Early Diagnosis Is Critical You Are Not Alone
Change Font Size:  
 

BioDiem delivers more positive results for eye disease drug

Type:  Drug-based Therapy  

BioDiem (ASX: BDM) has strengthened the preclinical case for its BDM-E eye disease drug with further positive results from formal studies that will help progress out-licensing opportunities for the drug.

BDM-E has received Orphan Drug designation from the United States Food and Drug Administration for the treatment of the inherited degenerative eye disorder, retinitis pigmentosa.

The results, which were presented at the International Society for Eye Research meeting in Berlin recently, confirm the potential of BDM-E to reduce formation of abnormal blood vessel growth; reduce the signs of damage typical to retinitis pigmentosa; and improve the function of the retina and inhibit the death of cells imperative for sight.

 

See the article at www.proactiveinvestors.com.au/companies/news/31580/biodiem-delivers-more-positive-results-for-eye-disease-drug-31580.html